Mesothelioma
• Mesothelioma Cause
• Mesothelioma
Symptoms
• Mesothelioma
Diagnosis
• Mesothelioma
Stages
Treatment Options
• Time Matters
• Traditional
Care
• New Approaches
• Nutrition
• Palliative Care
• Pain Management
Mesothelioma Specialists
• Choosing Your Doctor
• Your Health Care Team
• Choosing a Facility
• Cancer
Centers
• Travel &
Lodging
Clinical Trials
• Trial Basics
• Trial Phases
• Eligibility
• Current Trials
SUPPORT
Survivors & Fighters
• Belle McGuckin
• Bob Harthcock
• Willard Dahl
HELP
Financial Assistance, Compensation,
and Legal
Rights
Disclaimer and Sponsorship Information
If you would like to receive a free information packet** or have questions about mesothelioma,
call us at:
Toll-Free 1-877-FOR MESO (367-6376)
**Packet includes information on specialists, treatments, clinical trials, cancer links, and how to access legal and financial resources. You will be contacted by a Mesothelioma Web co-ordinator who will be available to discuss questions you might have.
|
|
|
MESOTHELIOMA NEWS ARTICLES
- NEW FDA Approves MESOMARK® Assay
for the Management of Mesothelioma Patients
First-in-Class RNAi Drug in Phase IIIB Confirmatory Trial for Unresectable Malignant Mesothelioma , January 30, 2007
- NEW FDA Approves MESOMARK® Assay
for the Management of Mesothelioma Patients
First in-vitro test for mesothelioma will enable doctors to more accurately detect recurrence and monitor treatment of patients, January 25, 2007
- NEW Alfacell Corporation Files for
U.S. Orphan Drug Designation for Onconase
Onconase is currently being evaluated in a confirmatory Phase IIIb clinical trial in mesothelioma treatment, December 21, 2006
- Additional Data From a Phase I Trial of XL647 in Patients
With Advanced Solid Tumors
Results demonstrate that XL647 is generally well tolerated and shows evidence of antitumor activity, November 9, 2006
- New study on the safety, tolerability, pharmacokinetics and
preliminary efficacy of INNO-305
INNOVIVE Pharmaceuticals Begins Enrollment in Phase I Study of INNO-305 Peptide Immunotherapy in AML, MDS, Mesothelioma and Non-Small Cell Lung Cancer, October 27, 2006
- More evidence that patients treated with Onconase have greater
median survival times than patients treated with doxorubicin alone
Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients With Mesothelioma, October 24, 2006
- Zolinza becomes first approved HDAC inhibitor
FDA approves Zolinza (vorinostat) for cutaneous T-cell lymphoma. This drug is being investigated in other indications including myeloma, mesothelioma and a variety of other cancers, October 10, 2006
- Alimta Researchers Recognized As Heroes Of Chemistry
Three researchers who led the discovery and development of the first drug approved to treat malignant pleural mesothelioma were named as Heroes of Chemistry by the American Chemical Society, September 11, 2006
- Progress on Clinical Development Program for ONCONASE(R)
in Malignant Mesothelioma
Pivotal trial is evaluating the effectiveness of ONCONASE plus doxorubicin in improving the survival of patients with unresectable malignant mesothelioma (UMM) over doxorubicin alone, August 31, 2006
- FDA tells Eli Lilly that their Alimta brochure is misleading
Patient manual omits facts and risk information about Alimta's safe and effective use, August 1, 2006
- News about onocology product candidate SS1P (renamed CAT-5001)
Cambridge Antibody Technology to take over development of drug that has shown results in clinical trials in patients with mesothelioma, ovarian and pancreatic cancer, July 28, 2006
- New Research Shows Unique Promise of Onconase in the Prevention
and Treatment of Mesothelioma
New research findings show that the elusive molecular mechanism that asbestos uses to provoke lung cancer may have been identified, June 27, 2006
- CuraGen and TopoTarget Announce Initiation of NCI-sponsored
Phase II Clinical Trial with PXD101 for Mesothelioma
PXD101 is a promising small molecule HDAC inhibitor being investigated for its role in the treatment of a wide range of solid and hematologic malignancies, June 20, 2006
- Alfacell Provides Update on ONCONASE Phase IIIb Confirmatory
Registration Trial; Releases First Interim Analysis Data
Overall median survival time (MST) favored the ONCONASE + doxorubicin treatment group (12 months) over the doxorubicin group. April 27, 2006 - Alfacell Achieves Full Patient Enrollment Milestone for the
Onconase Phase IIIb Registration Study in Unresectable Malignant Mesothelioma
Over 600 UMM patients have been enrolled in the Onconase Unrespectable Malignant Mesothelioma study , February 27, 2006 - Scientist Reveals His Hopes for Better Tumour Treatment
Hilary Calvert believes pemetrexed can be improved to provide longer term survival for some patients , March 3, 2006
- Alfacell Drug Trial Ahead of Schedule
Onconase Clinical Trial Enrollment Expected to Be Ahead of Schedule , January 30, 2006 - Alfacell Forms New Thoracic Cancer Advisory Board
Thoracic Cancer Advisory Board will support development of novel ribonuclease (RNase) therapies for the treatment of diseases such as mesothelioma and non-small cell lung cancer , January 27, 2006 - Update on Onconase Clinical Program
Over 300 patients are now enrolled in the international, confirmatory Phase IIIb trial evaluating ONCONASE® (ranpirnase) as a treatment for unresectable malignant mesothelioma, January 19, 2006 - Promising Research in Early Detection of Mesothelioma
A significantly higher concentration of osteopontin was detected in patients with diagnosed cases of mesothelioma compared to subjects with asbestos exposure, January 10, 2006 - Morphotek Announces IND Submission for MORAb-009, a Monoclonal
Antibody for the Treatment of Mesothelin-Expressing Cancers
Company will investigate MORAb-009, a monoclonal antibody targeting mesothelin, January 9, 2006 - INNOVIVE Pharmaceuticals Licenses WT1 Peptide Cancer Immunotherapeutic
from Memorial Sloan-Kettering Cancer Center
Vaccine is First WT1 Heteroclitic Peptide Immunotherapeutic to Specifically Target CD4 and CD8 Activation, January, 2006 - Gene Drug Gives Mesothelioma Patient Second Chance
First patient in clinical trial gets a second dose of Biogen Idec's new gene drug, October 28, 2005 - Novel therapies for pleural mesothelioma
Osteopontin reveals the early stages of pleural mesothelioma, October 12, 2005 - Thoracic Cancer Patients Find New Reasons for Hope with Alimta(®)
New data may provide important treatment advances in mesothelioma and lung cancer, July 5, 2005 - Gene Signature Could Revolutionize Cancer Care
Discovery should help doctors tailor treatment to specific tumor type, June 2, 2005 - Cancer seen in family members of asbestos workers
People who were exposed to asbestos through a family member who worked with the material appear to run the risk of developing mesothelioma, May 30, 2005 - Vitamin E helps battle mesothelioma
Alpha-TOS, which is closely related to Vitamin E, killed mesothelioma cancer cells in experiments with mice, May 22, 2005 - Ex-'silver bullet' re-aimed at cancer
Formerly hyped anti-angiogenesis drugs that starve tumors show new promise in use with chemotherapy, May 16, 2005 - SV40 not implicated in mesothelioma
Researchers eliminated contamination that has likely been the reason previous studies have implicated SV40, April 6, 2005 - New treatment options for some difficult cancers improve
survival and quality of life
Surgery combined with inserting heated chemotherapy drugs directly into the abdomen can improve survival rates, March 7, 2005 - Woman Diagnosed With Mesothelioma Gets New Results
Karen Grant's treatment seems to have had positive results. January 7, 2005 - Coramsine offers hope to mesothelioma patients
Researchers excited about new chemotherapy drug coramsine. November 25, 2004
- Coramsine reported effective in treating and preventing mesothelioma
in a mouse model of the cancer
Australia's Solbec Shares Soar After Cancer Drug Find. November 23, 2004, coramsine - No Role For Simian Virus 40 In Human Pleural Mesotheliomas
Researchers at Memorial Sloan-Kettering Cancer Center found no evidence for a significant role for SV40 in human mesotheliomas
- Experimental Surgery Gives Cancer Patient Hope
Very aggressive combination of surgery and chemotheraphy. September, 2004 - Studies Find No Evidence That SV40 is Related to Human Cancer
Further evidence that exposure to simian virus 40 (SV40) is not associated with mesothelioma in humans. August, 2004 - SBP002 Boosts the Immune System
Press Release from Solbec. June, 2004
 Older news stories |
Breaking mesothelioma news |
Copyright © 1998 - 2007